Scynexis. has filed a patent for an injectable composition of single bilayer vesicles containing enfumafungin derived triterpenoid antifungal compounds. These compositions can be administered intravenously to treat or prevent fungal infections, with reduced local injection site reactions. The compounds are inhibitors of (1,3)-ß-D-glucan synthesis and are effective against systemic fungal infections caused by Candida and Aspergillus species. GlobalData’s report on Scynexis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Scynexis, Peptide pharmacophores was a key innovation area identified from patents. Scynexis's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230277455A1) describes an injectable composition for treating fungal infections. The composition consists of an aqueous phase and one or more unilamellar vesicles that encapsulate a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate thereof. The concentration of the encapsulated compound in the composition ranges from about 0.01 to about 50 mg/mL. The aqueous phase contains sugar, specifically selected from monosaccharides, disaccharides, and combinations thereof, such as sucrose, trehalose, lactose, glucose, fructose, and galactose. The pH of the aqueous phase is maintained between 5.0 and 7.0.
The unilamellar vesicles in the composition are composed of phospholipid and cholesterol. The phospholipid can include phosphatidylcholine, phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, or combinations thereof. In particular, the vesicles can contain phosphatidylcholine and phosphatidylglycerol. The phosphatidylcholine can be selected from various types, such as dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, dilauroyl phosphatidylcholine, and dimyristoyl phosphatidylcholine. The phosphatidylglycerol can be dipalmitoyl phosphatidylglycerol, distearoyl phosphatidylglycerol, dilauroyl phosphatidylglycerol, or dimyristoyl phosphatidylglycerol.
The average particle size of the unilamellar vesicles is less than 150 nm, with a preferred range of 70 to 80 nm. The patent also includes methods for making the injectable composition, which involve encapsulating the compound of Formula (I) or its salt or hydrate in the vesicles using techniques like sonication, microfluidic mixing, or homogenization. The resulting vesicles can be sterilized and lyophilized for storage.
The patent also covers the use of the injectable composition for treating fungal infections, particularly those caused by Candida spp. or Aspergillus spp. The method involves intravenously administering the composition to a subject in need of treatment, including humans. The patent further describes a similar injectable composition for treating fungal infections caused by a compound of Formula (IIa) or its salt or hydrate, specifically Candida spp. or Aspergillus spp.
Overall, this patent presents an injectable composition containing unilamellar vesicles encapsulating specific compounds for the treatment of fungal infections. The composition's formulation, including the presence of sugar and specific phospholipids, as well as the method of administration, make it a potentially effective treatment option for fungal infections caused by Candida spp. or Aspergillus spp.
To know more about GlobalData’s detailed insights on Scynexis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
